This repository is under review for potential modification in compliance with Administration directives. Close 
| Shipment Date (yyyy-mm) | Principal Investigator | Project | Type | Specimen Number | Data Upload to ADNI/LONI (yyyy-mm-dd) |
|---|---|---|---|---|---|
| Samples to be shipped | Dr. Stephen Pasternak, University of Western Ontario, Robarts Research Institute | Brain Microparticle from Plasma: Non-Invasive “Brain Biopsies” for Improved Neurological Diagnosis | Plasma | 755 plasma | Samples to be shipped |
| 2025-08 | Allan Levey, Emory University | Proteomic study using plasma samples | Plasma | 604 | 2026: Anticipated |
| 2025-04 | Toledo Atucha, Juan, Houston Methodist, Texas | Biomarkers of Inflammation | Serum | 220 | 2026: Anticipated |
| 2024-12 | Dr. Dan Asby, University of Bristol, UK; Dr. Scott Miners, University of Bristol, UK | Markers of neurovascular damage, sPDGFRB and Angiopoitein-2(ANGPT2) | Serum & CSF | 225 serum and 75 CSF | 2025-10-01 |
| 2024-10 | Dr. Johanna Williams, University of Otago Dementia Prevention Research Clinic; Dr. Diane Guevremont, University of Otago; Dr. Wickliffe Abraham, University of Otago; Dr. Warren Tate, University of Otago | RNA in ADNI cog impaired/Amyloid PET+ and cognitively unimpaired/Amyloid PET- | Plasma | 199 plasma | 2026-01-01 |
| 2024-01 | FNIH BC/ADNI (Dr. Hartmuth Kolb, Janssen) | Ptau pilot add on to ptau feasibility study of the Aβ42/40 "round robin" study | Plasma | 130 + 6QC plasma | 2024-03-01 |
| 2023-12 | Dr. Cornelis Blauwendraat, NIH; Dr. Russ Lebovitz, Amprion; Dr. Duygu Tosun, University of California, San Francisco | SAA for detection of Lewy Body pathology in CSF longitudinal samples | CSF | 407 longitudinal CSF | 2024-03-01 |
| 2023-09 thru 2024-01 | FNIH BC/ADNI (C2N, Fujirebio, Quanterix, Roche) | Aβ42/40, ptau217, ptau181, GFAP, NfL trajectories in relationship to amyloid PET trajectories | Plasma | 3537 plasma to C2N 1179 plasma to Fujirebio 1179+1063 + 3 plasma to Quanterix 1179 plasma to Roche (Plus EQC samples to each of the above provided by University of Gothenburg) | 2024-06-01 |
| 2023-11 | C2N | Aβ42/40, ptau217/nonPtau217 ratio, IP/LC/MSMS | Plasma | 300 plasma from autopsied and 1527 plasma from HC/MCI/AD | 2026:Anticipated. Investigators applied for a new study on this batch of samples |
| 2023-05, 2023-08, and 2023-12 | Dr. Cornelis Blauwendraat, NIH; Dr. Russ Lebovitz, Amprion; Dr. Duygu Tosun, University of California, San Francisco | SAA for detection of Lewy Body pathology in CSF | CSF | 2,065 CSF from autopsy & from baseline premortem AD/MCI/HC; longitudinal | 2023-10-01 |
| 2023-03 | Dr. Ivana Delalle, Brown University; Dr. A Fisher, DZNE; Dr. Andrew Saykin, Indiana University | miRNA’s as diagnostic & prognostic markers of AD | Serum | 900 serum across AD/MCI/HC | 2024-07-01 |
| 2022-12 | Dr. Allan Levey, Emory University | Proteomic study using plasma samples matching CSF from May 2022 study | Plasma | 824 plasma | 2026-01: NULISA; 2026: Anticipated - Proteomics |
| 2022-05 | Dr. Allan Levey, Emory University | CSF AMP AD-2 Proteome | CSF | 833 baseline CSF | 2023-07-01 |
| 2021-06 and 2022-04 | Dr. Ivana Delalle, Brown University | miRNA | Plasma | 180 plasma 60 HC, 60 MCI, 60 AD + 10 replicates | 2026: Anticipated |
| 2019-08 | Dr. Kina Hoglund, Dr. Kaj Blennow Molndal, Sweden {ELISA, Simoa} | Novel markers of tau pathology & synaptic loss (TAU368 & GAP-43) | CSF | 1,286 ADNIGO/2 baseline + longitudinal CSF, 20 replicates | 2021-06-01 |
| 2023-06 | Dr. Valerie Daggett, AltPep Corporation, University of Washington | A Soluble Oligomer Binding Assay for Early Detection of Toxic Aβ Oligomers in Patients on the Alzheimer’s Disease Continuum | Plasma | 869 plasma from AD/MCI/HC | 2026: Anticipated |
| 2023-03 | Dr. Patrick Oeckl, Research Group Leader at German Center for Neurodegenerative Diseases (DZNE), Dr. Markus Otto, Director of Department of Neurology, Martin-Luther-University Halle-Wittenberg, Halle (Saale) | Longitudinal changes of the synaptic blood marker Beta-Synuclein in the ADNI cohort and relation to imaging and fluid biomarkers | Serum | 300 CN, 300 MCI at baseline, 300 AD | 2026: Anticipated |
| 2022-03 | Paul Kinnon, Diamdem | Diadem-Alzosure® Predict Clinical Validation | Plasma | 650 plasma | 2022-07-01 |
| 2023-01 | Dr. Hussein Yassine, University of Southern California, Dr. Dobrin Nedelkov, Isoformix, Dr. Wendy Mack, University of Southern California, Dr. Duke Han, University of Southern California, Dr. Meredith Braskie, University of Southern California | HDL particles and apoE glycosylation and lipid content in Alzheimer’s disease | Plasma | 188 plasma, 184 CSF | 2023-09-01 |
| 2022-12 | Fujirebio | LumipulseG β-Amyloid Plasma 1-42, 1-40 and Ratio | Plasma | 130 plasma | 2023-01-01 |
| 2022-02 | Dr. Dennis Selkoe, Brigham and Women's Hospital | Mechanism-based Plasma Biomarkers for AD diagnosis and prognosis (Plasma oAβ, Plasma NT1-tau) | Plasma | 829 plasma from 275 HC, 379 MCI, 131 AD | 2023-09-01 |
| 2021-08 | Dr. Michael Pontecorvo, Eli Lilly & Co, Dr. Ming Lu, Avid Radiopharmaceuticals | Diagnostic Performance Against the Brain PET Imaging Findings: Evaluation of a Novel Plasma ATN Biomarker Assay | Plasma | 291 plasma from 279 unique participants plus 10 replicate samples | 2025-06-01 |
| 2021-05 | Dr. Carlos Cruchaga, Washington University | sTREM2: CSF-derived miRNA’s as AD biomarkers in Plasma | Plasma | 367 Plasma 10 replicates | 2026: Anticipated |
| 2020-11 | Dr. Julie Saugstad, Oregon Heath and Science University | CSF-derived miRNA’s as AD biomarkers in Plasma | Plasma & CSF | 80 Plasma, 80 matched CSF for HC 80 Plasma, 80 matched CSF for AD 5 CSF replicates, 5 plasma replicates | 2023-02-01 |
| 2021-04 | Dr. Allan Levey, Emory University | CSF proteome | CSF | 719 CSFs matched to Rima K-D serum 10 replicates | 2023-07-01 |
| 2020-07 | FNIH BC plasma Aβ study group | Round robin for plasma Aβ42/40; p-tau pilot | Plasma | 130 ADNI GO/2 to each of 6 participating labs | 2021-06-01; 2022-11: ptau and updated 2023-12 |
| 2019-11 | Dr. Randall Bateman, Washington University School of Medicine | Aβ42/Aβ40 in CSF & plasma | CSF/Plasma | 638 plasma 487 CSF | 2022-11-01 |
| 2018-07 | Dr. Robert Nagele, University of Medicine and Dentistry of New Jersey, Rowan University, Durin Technologies, Inc. (Autoantibody Array) | Autoantibodies for AD detection | Serum | 406 ADNI1/GO/2 Baseline + Longitudinal Samples, 10 replicates | 2018-12-18 |
| 2018-03 | Dr. William Hu, Emory University Center for Neurodegenerative Diseases | CSF Cytokines/Chemokines IA | CSF | 388 ADNIGO/2 Baseline + longitudinal Samples, 10 replicates | 2019-01-04 |
| 2018-01 | FNIH BC/Caprion Proteome Inc., Washington DC/Montreal, Quebec, Canada {LC/MSMS} | CMGA, NPTX2, VGF, CG2, FABP mrm/mass spectrometry | CSF | 730 ADNI1, GO, 2 CSF Longitudinal Samples, 20 replicates | 2019-04-01 |
| 2017-11 | Dr. Randall Bateman, Washington University School of Medicine | Ab42/Ab40 in plasma of FBP+ / FBP- mrm/mass spectrometry | Plasma | 200 ADNI GO/2 Baseline Plasma Samples, 20 replicates | 2019-06-01 |
| 2017-10 for EI/FRB/MSD; 2018-10 for S/S | Euroimmune, Fujirebio MSD, Saladax/Siemens | New immunoassays for established AD biomarkers | Residual CSF | EI: 120 + 20 pool samples FRB: 422 + 20 pool samples MSD: 250 + 20 pool samples S/S: 373 + 20 pool samples | 2018-08-9: MSD; 2019-04-19: Euroimmune; 2019-07-01: FRB |
| 2017-09 | Dr. Carlos Cruchaga, Washington University, and Marc Suarez-Calvert, DZNE, Germany {Immunoassays} | sTREM2 & Progranulin | CSF | 1859 ADNI 1, GO, 2 BASELINE + Longtitudinal samples | 2018-02-23 |
| 2017-08 | Dr. Henrik Zetterberg, Molndal, Sweden {Simoa} | NFL & Tau diagnosis/prognosis p-tau181 added | Plasma | 3762 ADNI 1, GO, 2 longitudinal aliquot samples 20 replicates | 2018-10-13: NfL; 2020-06: p-tau181 |
| 2017-05 | Dr. Jing Zhang, Harborview Medical Center, University of Washington School of Medicine | a-Syn, Tau, Ab for AD Diagnosis | Plasma | 310 ADNI 1, GO, 2 samples 10 replicates | 2020-08-31 |
| 2017-03 | Dr. Dan Rader, Perelman School of Medicine, University of Pennsylvania | Cholesterol efflux | Serum | 795 ADNI 1 baseline samples 20 replicates | 2018-04-01 |
| 2016-07 | Dr. Rima Kaddoura-Daouk, Duke University {multiple LC/MSMS} | Metabolic networks | Serum | 905* ADNIGO/2 BL samples 15 triplicates Each sub-aliquotted: 6,335 total | 2017-01-01 |
| 2015-09 | Dr. Ian Sherriff, Araclon Biotech | Aβ1-42 and Aβ1-40 IA | Plasma | 784 ADNI1, GO, 2 longitudinal aliquot samples 759 PLA aliquots 25 Replicates | 2016-02-16 |
| 2015-03 | Dr. Jing Zhang, Harborview Medical Center, University of Washington School of Medicine | Total α-syn, Ser129, Phosphorylated α-syn, IA | CSF | *372 ADNI1 Baseline CSF aliquots samples *transferred from Geoff Baird 461 ADNI1, GO, 2 longitudinal aliquot samples 446 CSFs 15 Replicates | 2016-09-01 |
| 2014-09 | Dr. Kaj Blennow, PI Clinical Neurochemistry Lab | Tau Plasma High sensitivity IA | Plasma | 595 ADNI1 aliquot samples 579 Baseline PLA 16 Replicates | 2015-08-04 |
| 2014-07 | Dr. Allan Levey, Emory University School of Medicine | DDE** Mass spectrometry | Plasma | 221 ADNI1 aliquot samples 211 Baseline PLA 10 replicates | 2014-11-12 |
| 2014-05 | Dr. Kaj Blennow, PI Clinical Neurochemistry Lab | Cerebrospinal fluid levels of neurogranin Neurofilament Light (NFL) | CSF | 416 ADNI1 aliquot samples 400 Baseline CSFs 16 Replicates | 2014-08-20 |
| 2014-05 | Dr. Rima Kaddurah-Daouk, Duke University | Metabolic Pathways and Networks in Alzheimer’s Disease Mass spectrometry | Serum | 833 ADNI1 aliquot samples 813 Baseline SER 20 Replicates | 2015-08-14 |
| 2013-10 | Dr. Courtney Sutphen, Washington University School of Medicine, Lab of Drs. Anne Fagan & David Holtzman | YKL-40 and VILIP-1 in Longitudinal CSF sample sets | CSF | 612 ADNI1, GO, 2 longitudinal aliquot samples 597 CSFs 15 Replicates | 2015-07-15 |
| 2012-09 | PI: Dr. Lee Honigsberg, Genentech, co-Is: Dr. Nicholas Lewin-Koh, Genentech, Dr. Angus Nairn, Yale School of Medicine, Dr. Leslie Shaw, University of Pennsylvania, Dr. Dan Spellman, Merck Research Laboratories, Kristin Wildsmith, Genentech, Scientific Program Manager: Dr. Steve Hoffmann, The FNIH Biomarkers Consortium | CSF proteomic study Caprion using mrm mass spectrometry | CSF | 306 ADNI1 aliquot samples 290 Baseline CSFs 16 Replicates | 2014-04-04 |
| 2012-09 | Dr. Robert Nagele, University of Medicine and Dentistry of New Jersey, Rowan University, Durin Technologies, Inc. | Autoantibody biomarkers for detection and diagnosis of Alzheimer’s disease | Serum | 100 ADNI1 aliquot samples 50 Baseline MCI 50 Baseline NL | 2012-11-01 |
| 2012-05 | PI: Dr. Geoff Baird, University of Washington, co-Is: Dr. Thomas Montine, University of Washington, Elaine Peskind, University of Washington | Analyzing the CSF proteome with an oligonucleotideaptamer array | CSF and Plasma | 727 ADNI1 aliquot samples 372 Baseline CSFs and matching 355 PLA | 2016-09-21 Samples forwarded to Jing Zhang, PI |
| 2012-01 | PI: Dr. Lee Honigsberg, Genentech, co-Is: Dr. Nicholas Lewin-Koh, Genentech, Dr. Angus Nairn, Yale School of Medicine, Dr. Leslie Shaw, University of Pennsylvania, Dr. Dan Spellman, Merck Research Laboratories, Kristin Wildsmith, Genentech, Scientific Program Manager: Dr. Steve Hoffmann, The FNIH Biomarkers Consortium | Pilot Study CSF proteomics project Caprion using mrm mass spectrometry* PPSB Proteomics | CSF | 25 ADNI1 aliquot samples 20 Baseline CSFs: 10 AD, 10 NL and 5 aliquots of a CSF pool | 2014-04-04: with the main mrm MSMS Proteomic Study |
| 2011-09 | PI: Dr. Mary Savage, Merck Research Laboratories, co-I: Dr. Dan Holder, Merck Research Laboratories, Scientific Program Manager: Dr. Judy Siuciak, the FNIH Biomarkers Consortium | BACE and sAPP in CSF | CSF | 402 ADNI1 aliquot samples 382 Baseline CSF 20 Replicates | 2012-04-24 |
| 2011-08 | PI: Dr. William Potter, FNIH Biomarker Consortium co-Is: Dr. Eve Pickering, Pfizer, Dr. Mitch Kling, University of Pennsylvania, Dr. Leslie Shaw, University of Pennsylvania, Dr. Fred Immerman, Scientific Program Manager: Dr. Judy Siuciak, The FNIH Biomarkers Consortium | CSF proteomic study RBM* PPSB Proteomic studies | CSF | 317 ADNI1 aliquot samples 311 Baseline CSFs 16 Replicates | 2012-01-03 |
| 2011-03 | Dr. Jing Zhang, Harborview Medical Center University of Washington School of Medicine | ADNI RARC CSF Proteomic study | CSF | 390 ADNI1 aliquot samples Baseline CSFs: 92 AD, 187 MCI, 111 NC | 2013-03-11 |
| 2010-05 | 2010-2011: PI: Dr. Holly Soares (2010-2011), Pfizer, Statistical analyses: Dr. Eve Pickering, Pfizer, Dr. Fred Immerman, Pfizer, co-Is: Dr. William Potter, FNIH Biomarker Consortium, Dr. Max Kuhn, Pfizer, Dr. David Shera, Merck, Dr. Mats Ferm, AstraZenecat, Robert Dean, Eli Lilly, Adam Simon, Merck, Frank Swenson, Pfizer, Judy Siuciak, FNIH Biomarkers Consortium, June Kaplow, Eisai Medical Research, Madhay Thambisetty, NIA, Panayiotis Zagouras, Pfizer, Walter Koroshetz, National Institute of Neurological Disorders and Stroke, Hong Wan, Pfizer, John Trojanowski, University of Pennsylvania, Leslie M Shaw, University of Pennsylvania; Scientific Program Managers: Dr. David Lee, FNIH Biomarkers Consortium, and Dr. Judy Siuciak, FNIH Biomarkers Consortium 2011-2013: PI: Dr. William Potter, FNIH Biomarker Consortium, co-Is: Dr. Eve Pickering, Pfizer, Dr. Fred Immerman, Pfizer; Statistical analyses: Dr. Mitch Kling, University of Pennsylvania | Plasma proteomic study Rules Based Medicine (RBM)* PPSB Proteomic studies | Plasma & CSF | 1065 ADNI1 aliquot samples Baseline PLA: 394 MCI, 111 AD, 57 NL Year 1 PLA: 349 MCI, 98 AD, 56 NL 317 ADNI1 aliquot samples 311 Baseline CSFs 16 Replicates | 2010-11-01 |
| 2010-03 | Dr. John McIntyre, St. Francis Hospital | Redox Reactive Autoantibodies in ADNI subjects RARC/study phase 2 | Serum | 90 ADNI1 aliquot samples Baseline SER: 30 NC, 30 MCI and 30 AD | 2011-07-21 |
| 2009-07 | Dr. John McIntyre, St. Francis Hospital | Redox Reactive Autoantibodies in ADNI subjects, RARC/study phase 1 | Serum | 18 ADNI1 aliquot samples Baseline SER: 6 NC, 6 MCI and 6 AD | 2009-11-29 |
| 2009-07 | Dr. Lucas Restrepo, David Geffen School of Medicine at UCLA | Immuno signature of Alzheimer’s Disease: using a blood plasma test | Plasma | 100 ADNI1 aliquot samples Baseline PLA: 50 AD & 50 NL | Study not completed |
| 2007-12 | Dr. Andy Saykin, Indiana University, Dr. Dietrich Stephan, Indiana University, Dr. Steven Potkin, UC Irvine | Whole genome analysis of ADNI1 cohort following DNA extraction(at Cogenics) Genetic association analysis of the ADNI 1 cohort | Whole blood | 807 ADNI1 aliquot samples ADNI 1 Screening/Visit1 ApoE residual samples | 2009-03-16 |
| Shipment Date | Principal Investigator | Project | Type | Specimen Number |
|---|---|---|---|---|
| 2008-05-07 | Alison Goate, Washington University | Attempt to replicate genetic associations observed between CSF biomarker and neuroimaging phenotypes in samples collected at Washington University | DNA | 803 |
| 2010-08-11 | Keoni Kauwe, Brigham Young University | mtGCN phenotyping and ADNI phenotype data to examine the association between mtGCN and dementia and other phenotypes of interest | DNA | 806 |
| 2011-10-18 | Carlos Cruchaga, Washington University | Molecular testing to look for APP mutation | DNA | 2 |
| 2012-01-17 | Matthew Blurton-Jones, UC Irvine | "Proof of concept" to demonstrate measurements of mitochondrial function and has relevance for clinical diagnosis of AD | Cell Line | 20 |
| 2013-10-08 | Holly Soares, Bristol-Myers Squibb Company | RNA expression profiling to understand association of transcript profiles | Whole Blood | 811 |
| 2014-05-07 | Zoran Brkanac, University of Washington | Sequence candidate genes for association with AD | DNA | 576 |
| 2014-12-01 | Carlos Cruchaga, Washington University | Identifying of risk and protective variants, using WGS and specific APOE genotypes | DNA | 808 |
| 2016-08-29 | Abbvie | Methylation Project | DNA | 1919 |
| 2016-08-29 | Abbvie | Telomere Project | DNA | 1919 |
| 2016-08-29 | Laura P.W. Ranum, University of Florida | Methylation Project | DNA | 1 |
| 2016-08-29 | Laura P.W. Ranum, University of Florida | Telomere Project | DNA | 1 |
| 2016-11-07 | Jue Lin, University of California San Francisco | Methylation Project | DNA | 1920 |
| 2016-11-07 | Jue Lin, University of California San Francisco | Telomere Project | DNA | 1920 |
| 2017-07-31 | Matthew Huentelman, Tgen | Validating results with WES using different technology | DNA | 22 |
| 2018-02-19 | Julie Rutten, Leiden University | Confirmation of a variant | DNA | 1 |
| 2018-11-13 | Jerry Schellenberg, University of Pennsylvania | Confirmation of variant finding in ADSP | DNA | 1 |
| 2019-04-23 | Jerry Schellenberg, University of Pennsylvania | SV in genes that could increase or decrease risk for AD | DNA | 7 |
| 2020-12-21 | Jerry Schellenberg, University of Pennsylvania | Confirmation of finding from ADSP data | DNA | 1 |
| 2021-01-21 | Bruno Vellas, Toulouse University Hospital | RBCs for the ADNI-3 study | RBC | 849 |
| 2021-11-16 | Mark Ebbert, University of Kentucky | Extracted DNA for long read sequencing to look for a specific rare variant | Cell Line | 1 |
